Abstract
Introduction
Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease with manifestations ranging from mild to life-threatening organ dysfunction. There is wide variability in the reported incidence and prevalence rate globally, particularly in low and middle-income countries. Nigeria had very few isolated reports of SLE from private and public hospitals Therefore, we conducted this large multi-center descriptive study to determine the sociodemographic, clinical profile, laboratory patterns, and treatment among Nigerian lupus patients.
Methods
A retrospective hospital-based study of all SLE patients seen over 4 years (January 2017 to December 2020) was conducted at 20 rheumatology clinics spread across the 6 geopolitical zones of Nigeria. All patients 18 years and above satisfying the American College of Rheumatology (ACR) 1997 and/or the Systemic Lupus International Collaboration Clinics (SLICC) 2012 classification criteria for SLE were enrolled. Patients with other Rheumatic and Musculoskeletal Diseases (RMDs) not in keeping with SLE and Patients with incomplete data were excluded. Data was analysed using SPSS version 23.0 software.
Results
A total of 896 patients with SLE were included in the final analysis with a mean age ± SD of 34.47 ± 11 and a female to male ratio of 8.1:1. Synovitis was reported by 61.6% of patients, while 51%, 19.9% and11.4% patients reported acute, sub-acute and chronic lupus rashes respectively. ANA was positive in 98.0% with titers ranging from 1:80 to 1:64,000.
Conclusion
SLE is not rare in Nigeria. Most patients were female in their 3rd to 4th decades of life. There is a delayed presentation to a rheumatology facility. Arthritis and mucocutaneous manifestations were the most frequent presentation.
Key Points •This study presents the first national data on SLE in Nigeria •This study showed that SLE is not rare in Nigeria in contrast to previous reports •There appear to be ethnic disparity in the frequency of lupus among Nigerians •Nigerians with lupus have very high titer of ANA |
Similar content being viewed by others
Data availability
Data can be provided on request and after approval by all authors.
References
World Lupus Federation (2020) World Lupus Federation Global Survey 2020- Finds lupus greatly impacts physical function and quality of life. https://worldlupusfederation.org/2020/05/07/world-lupus-federation-global-survey-2020-topline-summary/ Accessed 21 February 2022
Barber MRW, Drenkard C, Falasinnu T, Hoi A, Mak A, Kow NY, Svenungsson E, Peterson J, Clarke AE, Ramsey-Goldman R (2021) Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol 17:515–532. https://doi.org/10.1038/s41584-021-00668-1
Fatoye F, Gebrye T, Mbada C (2022) Global and regional prevalence and incidence of systemic lupus erythematosus in low-and-middle-income countries: a systematic review and meta-analysis. Rheumatol Int. https://doi.org/10.1007/s00296-022-05183-4
Essouma M, Nkeck JR, Endomba FT, Bigna JJ, Singwe-Ngandeu M, Hachulla E (2020) Systemic lupus erythematosus in Native sub-Saharan Africans: A systematic review and meta-analysis. J Autoimmun. https://doi.org/10.1016/j.jaut.2019.102348
Adelowo O, Mody GM, Tikly M, Oyoo O, Slimani S (2021) Rheumatic diseases in Africa. Nat Rev Rheumatol 17:363–374. https://doi.org/10.1038/s41584-021-00603-4
Adelowo OO, Ojo O, Oduenyi I, Okwara CC (2010) Rheumatoid arthritis among Nigerians: the first 200 patients from a rheumatology clinic. Clin Rheumatol 29:593–597
Emorinken A, Dic-Ijiewere MO, Erameh CO, Ugheoke AJ, Agbadaola OR, Agbebaku FO (2021) Clinical and laboratory profile of systemic lupus erythematosus patients at a rural tertiary centre in South-South Nigeria: experience from a new rheumatology clinic. Reumatologia 59:402–410. https://doi.org/10.5114/reum.2021.111714
Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725. https://doi.org/10.1002/art.1780400928
Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR et al (2012) Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64:2677–2686. https://doi.org/10.1002/art.34473
Markowitz GS, D’Agati VD (2007) The ISN/RPS 2003 classification of lupus nephritis: an assessment at 3 years. Kidney Int 71:491–495. https://doi.org/10.1038/sj.ki.5002118
Khanfir MS, Houman MH, Cherif E, Hamzaoui A, Souissi S, Ben Ghorbel I et al (2013) TULUP (TUnisian LUPus): a multicentric study of systemic lupus erythematosus in Tunisia. Int J Rheum Dis 16:539–546
El Hadidi KT, Medhat BM, Abdel Baki NM, Abdel Kafy H, Abdelrahaman W, Yousri AY et al (2018) Characteristics of systemic lupus erythematosus in a sample of the Egyptian population: a retrospective cohort of 1109 patients from a single center. Lupus 27:1030–1038
Budhoo A, Mody GM, Dubula T, Patel N, Mody PG (2017) Comparison of ethnicity, gender, age of onset and outcome in South Africans with systemic lupus erythematosus. Lupus 26:438–446
Adelowo OO, Ojo O, Oduenyi I (2012) Autoantibodies in Nigerian lupus patients. Afr J Med Sci 41:177–181
Symmons DP (1995) Frequency of lupus in people of African origin. Lupus 4:176–178
Bae SC, Fraser P, Liang MH (1998) The epidemiology of systemic lupus erythematosus in populations of African ancestry: a critical review of the “prevalence gradient hypothesis.” Arthritis Rheum 41:2091–2099
Adwan M (2018) Clinical and Serologic Characteristics of Systemic Lupus Erythematosus in the Arab World: A Pooled Analysis of 3,273 Patients. Arch Rheumatol 33:455–463
Li M, Wang Y, Zhao J, Wang Q, Wang Z, Tian X, Zeng X (2021) Chinese SLE Treatment and Research Group (CSTAR) Registry 2009–2019: major clinical characteristics of Chinese patients with systemic lupus erythematosus. Rheumatol Immunol Res 2:43–47
Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P et al (1993) Systemic lupus erythematosus:clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European working party on systemic lupus erythematosus. Medicine (Baltimore) 72:113–124
Pons-Estel BA, Catoggio LJ, Cardiel MH, Soriano ER, Gentiletti S, Villa AR et al (2004) The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among “Hispanics.” Medicine (Baltimore) 83:1–17. https://doi.org/10.1097/01.md.0000104742.42401.e2
Maningding E, Dall’Era M, Trupin L, Murphy LB, Yazdany J (2020) Racial and ethnic differences in the prevalence and time to onset of manifestations of systemic lupus erythematosus: the California lupus surveillance project. Arthritis Care Res (Hoboken) 72:622–629
Gergianaki I, Garantziotis P, Adamichou C, Saridakis I, Spyrou G, Sidiropoulos P, Bertsias G (2021) High comorbidity burden in patients with sle: data from the community-based lupus registry of crete. J Clin Med 10:998. https://doi.org/10.3390/jcm10050998
Pryor KP, Barbhaiya M, Costenbader KH, Feldman CH (2020) Disparities in lupus and lupus nephritis care and outcomes among us medicaid beneficiaries. Rheum Dis Clin North Am 47:41–53. https://doi.org/10.1016/j.rdc.2020.09.004
Elbagir S, Elshafie AI, Elagib EM, Mohammed NA, Aledrissy MIE, Sohrabian A et al (2020) Sudanese and Swedish patients with systemic lupus erythematosus: immunological and clinical comparisons. Rheumatology (Oxford) 59:968–978
Li H, Zheng Y, Chen L et al (2022) High titers of antinuclear antibody and the presence of multiple autoantibodies are highly suggestive of systemic lupus erythematosus. Sci Rep 12:1687. https://doi.org/10.1038/s41598-022-05807-6
Han BK, Rathwell E, Ng B, Wener M (2018). Evaluation of Erythrocyte Sedimentation Rate As a Marker of Disease Activity in Patients with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 70 (suppl 10). https://acrabstracts.org/abstract/evaluation-of-erythrocyte-sedimentation-rate-as-a-marker-of-disease-activity-in-patients-with-systemic-lupus-erythematosus/. Accessed 21 February 2022
Akintayo RO, Akpabio AA, Kalla AA, Dey D, Migowa AN, Olaosebikan H et al (2021) The impact of COVID-19 on rheumatology practice across Africa. Rheumatology (Oxford) 60:392–398. https://doi.org/10.1093/rheumatology/keaa600
Shah R, Dey D, Pietzonka T, Obeng P, Ashiru B, Schiestl M, Cavey A, Nkansah E, Radiere G, Spector J, Scott C (2020) Determinants of use of biotherapeutics in sub-Saharan Africa. Trends Pharmacol Sci 42:75–84. https://doi.org/10.1016/j.tips.2020.11.012
Adelowo OO, Olisa O, Asekhame OT, Ojo O (2021) Biotherapies in medical practice: a review and the Nigerian experience. West Afr J Med 38:486–493
Acknowledgements
We acknowledge the International League of Associations for Rheumatology (ILAR) Project 2020 for funding the LURIN.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
None.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Osaze, O., Olaosebikan, H.B., Yerima, A. et al. Pattern of systemic lupus erythematosus in NIGERIA: a multicentre descriptive hospital-based study. Clin Rheumatol 42, 2787–2797 (2023). https://doi.org/10.1007/s10067-023-06672-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-023-06672-y